Killers by Design: How Innovative Gene-Engineering Fine-Tunes NK Cells as Next Generation Immunotherapies
Human Gene Therapy · 18.11.2026
DOI: 10.1177/10430342261477949 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Gene Therapy, online erschienen am 18.11.2026. Verfasst von Pia Kluge und 6 weiteren Autor:innen. Beteiligte Einrichtung: Experimental Immunology and Cell Therapy, Goethe University, Frankfurt am Main, Germany. Die Arbeit nennt 224 Literaturangaben.
Abstract (Originalsprache)
Natural killer (NK) cells have emerged as promising candidates for adoptive immunotherapies. Their natural cytotoxic capabilities and low incidence of side-effects such as cytokine release syndrome and immune effector cell-associated neurotoxicity, render NK cells a favorable alternative to T cells. Incorporation of a chimeric antigen receptor (CAR) has been shown to greatly enhance NK cell’s antitumor capacity. Nevertheless, CAR-NK cell therapies still face several challenges, such as low in vivo persistence, low tumor homing of the transfused cells and the effects of the immunosuppressive tumor microenvironment (TME). Genetic modifications of key cellular mediators show great potential to overcome these hurdles. While well-established viral engineering strategies are currently the most commonly used techniques, biosafety concerns, high costs, and labour-intensive protocols have encouraged innovation toward nonviral strategies. In this review, we describe recently established viral and nonviral technologies used for NK cell engineering, focusing on their respective advantages and disadvantages. In addition, we highlight the most important functional refinements and mechanistic characterizations of NK cells and genetically optimized NK cells in the context of the TME and how these advances can be progressed toward therapeutic translation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Experimental Immunology and Cell Therapy, Goethe University, Frankfurt am Main, Germany.
- German Cancer Consortium (DKTK), Heidelberg-partner site Freiburg, Germany.
- German Cancer Research Center (DKFZ), Heidelberg, Germany.
- Institute of Molecular Medicine, Albert Ludwigs University, Freiburg, Germany.
- LABMaiTE GmbH, Freiburg, Germany.
- Medical Department II and Chair for Cellular Immunotherapy, University Hospital Würzburg, Würzburg, Germany.
ORCID-Profile: Lea Rebecca Knapp, Tobias Bexte, Evelyn Ullrich
Zitieren
APA
Kluge, P., Knapp, L. R., Lai, K. Y., Sapre, A., Rasko, T., Bexte, T., & Ullrich, E. (2026). Killers by Design: How Innovative Gene-Engineering Fine-Tunes NK Cells as Next Generation Immunotherapies. Human Gene Therapy. https://doi.org/10.1177/10430342261477949
Vancouver
Kluge P, Knapp LR, Lai KY, Sapre A, Rasko T, Bexte T, et al. Killers by Design: How Innovative Gene-Engineering Fine-Tunes NK Cells as Next Generation Immunotherapies. Human Gene Therapy. 2026. doi:10.1177/10430342261477949
BibTeX
@article{Kluge2026,
author = {Kluge, Pia and Knapp, Lea Rebecca and Lai, Kuan-Yu and Sapre, Avani and Rasko, Tamas and Bexte, Tobias and Ullrich, Evelyn},
title = {Killers by Design: How Innovative Gene-Engineering Fine-Tunes NK Cells as Next Generation Immunotherapies},
journal = {Human Gene Therapy},
year = {2026},
doi = {10.1177/10430342261477949}
}
EUVIMED